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Abstract 
Glioma is the most common type of primary brain tumor in humans, and the second 
most common in canines. This tumor type originates from glial cells in the brain 
and is a genetic disorder caused by mutations in genes regulating important cellular 
functions. The current diagnosis of glioma is based on histopathological evaluations 
and gradings. The complexity of the disease requests advanced gene technologies 
and bioinformatics tools which can aid in the development of new and better diag-
nosis criteria and therapies. Using Genome wide association studies (GWAS) sev-
eral genes have been found to be associated with glioma. And with next generation 
sequencing (NGS) methods, large amounts of genetic information can be produced, 
stored and analyzed for a low cost. Glioma develops spontaneously in dogs in a 
similar fashion as in humans and is proposed as a model in glioma research. The 
findings of new genes associated with glioma can be used for gene, small molecular 
and immune therapies. Receptor tyrosine kinases VEGFR-1, VEGFR-2, EGFR-1, 
PDGFR, EGFR and c-MET have been found to be overexpressed in both canine 
and human gliomas, and growth-factor-targeted therapies have been proposed as 
treatment for gliomas in canine and humans. Gene therapies including methods as; 
conditionally cytotoxic therapies, suppression of angiogenesis, immune stimulation, 
tumor suppressors etc. are progressing in research and clinical trials. No therapy has 
yet been developed that alone can cure or slow the growth of glioma effectively, but 
several are in use for complementary treatment in humans. The use of dogs in glio-
ma research and clinical trials can hopefully provide novel findings on how to pro-
ceed with more effective therapies and earlier diagnosis. This is a review of the 
genetics behind glioma and how this information can be used in research for better 
treatment.  
Keywords: c-MET, Canine, Gene therapy, Genome Wide Association 
Studies (GWAS), Next generation sequencing (NGS), Glioma.  
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Abbreviations 
 
  
APC Antigen-presenting cell 
DC Dendritic cells 
GWAS Genome-wide association study 
HGFR Hepatocyte growth factor receptor (also called c-MET) 
INDEL Insertion or deletion 
LD Linkage disequilibrium 
mAb Monoclonal antibodies 
MHC Major histocompatibility 
NGS Next generation sequencing 
RTK Receptor tyrosine kinase 
SNP Single Nucleotide Polymorphism 
TNF Tumor necrosis factor 
WES Whole exome sequencing 
WGS Whole genome sequencing 
WHO World health organization 
GBM Glioblastoma multiform 
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1 Introduction 
Gliomas are the most common primary brain tumors in humans and in dogs 
(Schiffman & Breen, 2015) and are derivied from glial cells in the brain and cen-
tral nervous system (Goodenberger & Jenkins, 2012). The malignancy of the gli-
omas is internationally classified according to the World Health Organization 
(WHO) criteria based on histopathological evaluations and gradings; benign glio-
ma is graded as WHO grade I; Low-grade tumors as grade II; anaplastic as grade 
III; and the most malignant form of glioma, glioblastoma as grade IV (Louis, 
2006). 
Despite all the progress that has been made to identify, pathologically characterize 
and treat gliomas (Ostrom et al., 2014), the survival rate of patients with WHO 
grade II tumors usually survive 5 years, patients with WHO grade III tumors usu-
ally survive 2-3 years and survival of patients diagnosed with the most malignant 
tumor, WHO grade IV, depend largely upon whether or not treatments are effec-
tive and available, but usually not longer than one or one and a half year. The ma-
jority of patients diagnosed with glioblastoma do not survive the first year (Louis 
et al., 2007). There are some concerns regarding the classification scheme based 
on WHO-grading, the classification is based on visual criteria alone and the cate-
gories are not satisfactory for all cases. The classification is subjective and is not 
necessarily a good predictor of behavior, response or survival as a result of thera-
pies in individual patients and tumors. Thus, an improved classification systems 
for glioma is desired and may be essential for better outcomes in glioma patients 
(Louis et al., 2001).   
 
Cancer is caused by genome alterations, for example by several point mutations 
(Comprehensive genomic characterization defines human glioblastoma genes and 
core pathways, 2008), and the understanding of the genetic basis causing the dis-
ease is one of the biggest challenges in biomedical research (Genetic dissection of 
complex traits, Lander and Schork)(Karlsson & Lindblad-Toh, 2008). Glioblasto-
ma was the first cancer that was studied by The Cancer Genome Atlas (TCGA) 
(Cancer Genome Atlas Research Network, 2008), and three core pathways were 
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found to be altered; disrupted growth factor signaling dependent on the receptor 
tyrosine kinases (RTKs), activation of intracellular signaling of phosphoinositide 
3-kinase (P13K) and inactivation of the tumor suppressor genes retinoblastoma 
(RB) and tumor protein 53 (TP53) (Comprehensive genomic characterization de-
fines human glioblastoma genes and core pathways, 2008).        
 
The domestic dogs (Canis lupus familiaris) share many common diseases with 
humans including cancer, immune-mediated diseases, cardiovascular diseases and 
neurological diseases like epilepsy (Hayward et al., 2016). The canine genes that 
are associated with increased risk of disease development are often orthologous 
with humans (Karlsson & Lindblad-Toh, 2008). Dogs have been evolved in close 
relationship with humans often living in the same environment and sharing both 
space and food sources. In the last two centuries humans have selectively bred 
dogs with desired morphological or behavioral traits, often resulting in a popula-
tion bottleneck for different breeds. As a consequence of this artificial breeding 
and limitations of genetic diversity is somewhat limited, and certain dog breeds 
have a higher prevalence of specific diseases (Lindblad-Toh et al., 2005). This can 
be explained by enrichment of risk alleles as a result of random amplification dur-
ing population bottleneck, or as a result of hitch-hiking mutations near desired 
traits (Karlsson & Lindblad-Toh, 2008). This suggests that the number of loci 
underlying the disease is limited and genetic factors associated with disease will 
be easier to map in dogs than in humans (Lindblad-Toh et al., 2005).       
 
Gliomas occur spontaneously in dogs (Hayes et al., 1975) and share the same his-
topathological features as human gliomas, which allows similar diagnosis criteria 
and consequently canine glioma has been proposed as an excellent model for glial 
cell tumors in human (Schiffman & Breen, 2015). Glioma in dogs is classified 
using the same WHO grading criteria as in humans. This due to the clinical simi-
larities in the canine glioma compared to human gliomas (Herranz et al.). Howev-
er, canine gliomas are not always classified before treatment is administrated, 
compared to human gliomas where’s a histological diagnosis is required (Bentley 
et al., 2013). New classification methods is in the same fashion as in human glio-
mas, essential for better outcome in glioma patients. Studies aiming at defining 
genes that have abnormal expression in canine glioma have shown an increased 
expression of several genes encoding receptor tyrosine kinases such as VEGFR-1, 
VEGFR-2, EGFR, PDGFR and c-MET, which support the similarities to human 
gliomas (Dickinson et al., 2006)(Higgins et al., 2009).  
 
In this paper, I will review the findings of gene alterations in canine glioma and 
how the information can be used for improved diagnosis and therapies in dogs and 
humans. 
7 
 
 
8 
 
2 Literature survey  
Cancer is mainly a genetic disorder. Alterations in oncogenes, tumor suppressor 
genes or DNA repair genes caused by mutations inherited in germ cells or ac-
quired in somatic cells, cause abnormal regulation of cell growth and control 
mechanism ultimately resulting in tumor development. The uncontrolled growth 
and cell division increases the risk of additional mutations which can support tu-
mor growth and proliferation (Wong et al., 2011). Hanahan & Weinberg (2011) 
have proposed eight hallmarks to rationalizing the complexity of cancer. They 
comprise eight biological mechanisms acquired for development of tumors; sus-
taining proliferation signaling, evading growth suppressors, activating invasion 
and metastasis, enabling replicative immortality, inducing angiogenesis, resisting 
cell death reprogramming of energy metabolism and evading immune destruction. 
Each of these hallmarks is a potential therapeutic target. In the last years, other 
areas have also been proposed as therapeutic targets in cancer including epigenetic 
alterations and regulatory microRNAs (Hanahan & Weinberg, 2011). Approxi-
mately 90% of all known cancer-associated genes are linked to somatic mutations 
and only 20% are believed to be inherited mutations. Somatic mutations are usual-
ly classified as driver and passenger mutations. Driver mutations have an ad-
vantage for growth and/or survival, and are positively selected. Passenger muta-
tions have no functional consequence and has not been selected (Wong et al., 
2011). Today, malignant gliomas are treated with surgery combined with chemo-
therapy and radiotherapy. Gaining more knowledge about how certain genes is 
associated with the development of glioma is important for early detection and for 
new and more effective personalized therapies (Louis, 2006).       
2.1 Genome wide association studies (GWAS) 
Genome-wide association studies (GWAS) can be used to scan genomes of case 
populations and healthy populations as controls to identify regions associated with 
increased risk for diseas (Sayyab, 2014). GWAS is based on polymorphic markers 
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that is in linkage disequilibrium (LD) with a specific trait (Truvé, 2012), and uses 
millions of Single Nucleotide Polymorphism (SNPs) in humans (Edwards et al., 
2013) and over 170 000 of SNPs in dogs, who have restricting genetic diversity 
compared to humans, to map genetic risk factors associated with increased risk for 
certain diseases. So, if two populations (cases and control) are compared using 
several markers, and one allele for the case population was found significantly 
more frequent among the cases compared with the control group, that allele is said 
to be associated with a trait. However, gene association studies using case and 
control design have a pitfall, in the presence of subgroups with differing allele 
frequencies (population stratification) might cause false positive association   
(Truvé, 2012). Knowledge of genetic variants associated with traits such as certain 
diseases, can offer markers for early detection, diagnosis and personalized treat-
ment. The majority of identified SNPs (approximately 88%) are located in the 
intergenic or intronic regions and are most likely to interact with gene regulation 
(Edwards et al., 2013).   
Epigenetics is another important aspect in complex diseases as Glioma. Epigenet-
ics is the regulation of gene expression that is not dependent on the DNA sequence 
and it can be inherited or acquired (Wong et al., 2011). Epigenetic modifications 
refer to either DNA methylation of cytosines at CpG dinucleotide or various dif-
ferent histone modifications at particular amino acid residues, including methyla-
tion, acetylation and phosphorylation. Both DNA methylation, histone and chro-
matin modifications have large impact on chromatin structure and gene expres-
sion. Epigenetic patterns that increases cell growth and survival are, like driver 
mutations, positively selected for and is proposed as a target for cancer treatment 
(Wong et al., 2011). Sequencing studies of glioblastoma, the most malignant grade 
of glioma, in humans have identified mutations in several genes associated with 
chromatin modulation including isocitrate dehydrogenase (IDH-1 and IDH-2) that 
is associated with DNA methylation (Kondo et al., 2014).      
2.2 Nucleotide sequencing and Next generation sequencing 
(NGS) 
Sanger sequencing, a first generation sequencing method, have been used for over 
40 years in genome research and was the principal method for the completion of 
sequencing the human genome. The method has also made it possible to identify 
specific genes that are responsible for development of specific diseases. A newer 
genome sequencing method is called next generation sequencing (NGS), which 
can rapidly produce large amount of sequence data and is cheaper than first gener-
ation sequencing methods and makes it more obtainable for the average lab (Shyr 
& Liu, 2013). NGS is based on cyclic array’s where the DNA in iterative cycles 
get treated with enzymatic manipulation to become short reads and is collected as 
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imaging-based (optical) data every cycle, with multiple sequences read at once. 
Commercial products that uses this sequencing method includes Roche’s 454, 
Illumina’s Genome Analyser, SOLiD and Heliscop from Helicos (Magi et al., 
2010). With the giant potential of data that can be obtained from NGS at a relative 
low cost has made it possible to landscape more complex diseases like cancer. 
Several collaborative efforts such as the International Genome Consortium (ICGC) 
(International Cancer Genome Consortium et al., 2010) and The Cancer Genome 
Atlas (TCGA) projects are currently mapping the genomic landscape in humans. 
These collaborations will give us a better understanding of the genetics behind 
diseases, and will take us closer to the goal of developing personalized medicine. 
Using whole-genome sequencing (WGS) and whole-exome sequencing (WES); 
point mutations, insertions and deletions (INDELs), repetitions and structural vari-
ants can be identified, studied and compared to controls (Meldrum et al., 2011). 
Illumina HiSeq is one of the most popular choice of platforms for NGS, which 
uses reversible terminator chemistry (Bentley et al., 2008). However, alternative 
platforms for next generation sequencing are emerging which are not based on 
WGS or WES. One example is the Ion Proton platform that is based on semicon-
ductor technologies. This method generates high-quality sequence from large ge-
nomes in a relatively short period of time. Bioinformatic tools is then used to col-
lect and handle large amounts of data to understand the complexity of the disease 
and propose personalized treatment strategies (Sayyab, 2014).        
2.3 Bioinformatics – genetic variants 
One important challenge in NGS is to align billions of reads accurately and rapid. 
The massive data collection possible today makes it impossible to use old and 
traditionally alignment tools. For this reason, several new tools (short read align-
ers) have been developed that are much faster compared with the traditional align-
ers. Algorithms are used to quickly and efficiently align the billions of short reads, 
and most also be able to permit alignment of repetitive sequences, errors and var-
iations. Algorithms today most be improved  in order to identify structural variants 
with higher resolution (Magi et al., 2010). Several different softwares have been 
published with acquired algorithm criteria (Sayyab, 2014). The search for single 
nucleotide polymorphism (SNP) and inversion-deletion (INDEL) is important in 
the research. For example, these programs can also be used to identify loci that are 
either homozygous or heterozygous, the sequence quality of the obtained data and 
how well the genomic regions of interest are covered. A conditional likelihood of 
the nucleotides to exist at a specific position is also predicted using Baye’s rules 
(Magi et al., 2010).  
The alignment pipeline is important for a significant result, which includes sorting, 
merging and improving the alignment by duplicate removal, realignment and base 
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quality recalibration. Examples of tools used to predict functional significance of 
SNPs and INDELs are; GATK and SAMtool that can find single nucleotide vari-
ants, ANNOVAR software that categorize (annotate) obtained variants into coding 
or non coding single nucleotide variants and PolyPhen-2 (polymorphism pheno-
typing) is used to evaluate the functional consequence of missense SNPs. Poly-
Phen-2 predicts the possible structural and functional effect of single amino acid 
substitution (Sayyab, 2014).      
2.4 Gene therapy and other treatments of glioma 
Gene therapy is a collective name for a number of different therapies using genes 
to treat or prevent diseases.  
There are several different suggested treatment options for glioma, including con-
ditionally cytotoxic therapies, suppression of angiogenesis, immune stimulation 
and correction of mutations in tumor suppressors and oncogenes (Castro et al., 
2011). Conditionally cytotoxic therapies introduce a gene encoding an enzyme 
into the tumor cells, and on the delivery of a noncytotoxic prodrug converts it into 
a cytotoxic metabolite that will induce apoptosis. One big obstacle is that this en-
zyme must exclusively be expressed exclusively in tumor cells to be successful 
(Castro et al., 2011). 
Angiogenesis is the growth of blood vessels from pre-existing vessels. The capil-
laries are important for nutrition and metabolite exchange in all tissues, and essen-
tial for growth and proliferation of gliomas. Angiogenesis can be developed by 
sprouts, also called sprout angiogenesis, on endothelial cells, that grow when 
stimulated by vascular endothelial growth factor (VEGF-A). Most of these cells 
can also sense hypoxia and secrete VEGF-A that initiate angiogenesis (Adair & 
Montani, 2010). During angiogenesis, VEGF-receptors (VEGFR) get activated 
and induces production of platelet-activation factor (PAF) that increases vascular 
permeability (Hoeben et al., 2004). One other mechanism of angiogenesis is called 
intussuspective angiogenesis (also called splitting angiogenesis), this mechanism 
is less understood compared to sprout angiogenesis, but is a more rapid developed 
process involving splitting of a single vessel into two. Angiogenesis is important 
for tumor development, and by inhibition of promoters for angiogenesis such as 
VEGF the goal is to stop the tumor growth (Castro et al., 2011).  
Immune stimulation in cancer therapy is a highly exiting therapy for cancer treat-
ment right now. The immune response that is often elicited in tumors may be 
caused by tumor-specific antigens. However, most tumors develop a protection 
against this immune response. There are several cancer therapies aimed at improv-
ing the immune response both by gene therapies and as vaccines. One way to 
stimulate the immune response is by deliver tumor antigens using adenoviral ex-
pression. All tumor cells express tumor antigens that are recognized by the im-
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mune system. By engineering adenoviral vectors expressing this antigen as vac-
cines, the hope is to stimulate the immune system. Preclinical trials are showing 
promising results for some cancers, but have not been tested for gliomas. Another 
way to stimulate the immune response is to use interferons. Interferons are a group 
of ligands secreted by the cells in the presence of pathogens and they are involved 
in inflammation. Due to the highly specific immune response elicited by interfer-
ons, they are considered as valuable targets in gene therapy. IFN-α, a type I inter-
feron, has been shown to be an excellent cell cycle inhibitor which also induces 
apoptosis and stimulate the immune response. IFN-α treatment in human glioblas-
toma cell lines increases the expression of major histocompatibility complex I 
(MHC-I) molecules that are involved in antigen presentation leading to activation 
of the immune system. IFN-α has also been shown to reduce the tumor volumes 
when overexpressed in mice. There are several other mechanisms for immune 
stimulation including enhancement of T-cell activities and activation of dendritic 
cells (DC) (Castro et al., 2011). CD40 is a tumor necrosis factor (TNF) receptor 
superfamily member, and is expressed on antigen presenting cell (APC) such as B 
cells, monocytes and DCs. Ligation of CD40 on DCs will for an example increase 
the expression of MHC, and ligation of CD40 on B cells increase antigen presenta-
tion. By using agonistic CD40 monoclonal antibodies (mAb) the goal is to activate 
APCs followed by anti-tumor specific T cell responses (Vonderheide & Glennie, 
2013). The usage of CD40 as an immune stimulator has been tested in spontane-
ous canine malignant melanoma with good response and further development of 
clinical treatment is under progress for both dogs and humans (Westberg et al., 
2013).  
Cancer development, as discussed above, comes from normal precursors but has 
tendency to mutate key genes, also called driver genes, that regulates proliferation 
and apoptosis. Tumorigenesis requires mutations in several genes to progress. The 
genetics in glioma is relatively well established and this knowledge can be used to 
develop gene therapies to correct these mutations. Some of the pathways with 
established mutations in human glioma are P53/ARF, receptor tyrosine kinases 
RTK/RAS and PI3K/PTEN/Akt (Castro et al., 2011). P53 is responsible for regu-
lation of cell cycle and apoptosis. Mutations in this tumor suppressor gene will 
quickly convert it into an active tumor suppressor and transform cells to become 
malignant. Every division will increase the risk of new mutations, and with several 
mutations the risk of cancer development is higher. Due to the fact that cancer is 
caused by several mutations, correcting mutations in all these genes is most likely 
impossible and gene therapies aimed at achieving this very complicated. However, 
in some cases correction of a single mutation can be sufficient to induce apoptosis. 
One way to correct the mutation is by injecting vectors expressing the P53 wild 
type protein. Retroviral vectors have been used for gene replacement therapies 
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with the benefit of only acting on actively dividing cells compared to adenovirus-
es, for an example, that acts on all cells (Roth et al., 1999). 
 
In canine primary brain tumors, c-MET and other growths factor receptors includ-
ing receptor tyrosine kinases VEGFR-1, VEGFR-2, EGFR and PDGFR have been 
reported to be overexpressed in a similar fashion as in humans. This confirms the 
use of growth-factor specific therapies in dogs and the use of dogs as a model for 
human glioma (Dickinson et al., 2006).     
2.5 c-MET 
c-MET (also called hepatocyte growth factor receptor [HGFR]) is one of the most 
common genes found to be dysregulated in cancer (Liu et al., 2010). c-MET is a 
proto-oncogene that encodes the protein c-MET tyrosine kinase, which is a cell 
surface receptor expressed in epithelial cells of many organs. The c-MET protein 
precursor is proteolytically processed in the post-Golgi compartment, where it is 
cleaved into a 50 kDa α-subunit and a 147 kDa β-subunit that remain attached to 
each other by a disulphide bond. (Trusolino et al., 2010)(Organ & Tsao, 2011). 
The extracellular part of c-MET consists of three domains; the N-terminal (500 
residues) consists of an α-subunit and parts of the β-subunit and is folded into a 
semaphorine (Sema) domain, followed by the 50 residue plex-in-semaphorine-
integrin (PSI) domain that is connected to four immunoglobulin-plexin-
transcription (IPT) domains. The intracellular part of c-MET consists of; the jux-
tamembrane domain which negatively regulates the enzyme activity by recruiting 
cCBL using tyrosine Y1003, the kinase catalytic domain positively modulates 
enzyme activity by tyrosines Y1234 and Y1235, in the c-terminal there is a multi-
functional docking site (tyrosines Y1349 and Y1356) which recruit transducers 
and adapters when c-MET is active. Mesenchymal cells secrete the c-MET ligand 
hepatocyt growth factor (HGF), also called scatter factor (SF), as a single inactive 
polypeptide that is activated when cleaved into two (α and β) chains held together 
by a disulphide bond. HGF act as a multifunctional cytokine and regulates cell 
growth, proliferation, scattering, survival, motility and morphogenesis by activat-
ing the tyrosine kinase signaling cascade (Comoglio et al., 2008). When HGF 
docks into c-MET it results in homodimerization of the receptor and phosphoryla-
tion of tyrosines Y1234 and Y1235, in the subsequent step, tyrosines Y1346 and 
Y1356, located in the c-terminal of the molecule, become phosphorylated 
(Ponzetto et al., 1994). The phosphorylated tyrosines Y1346 and Y1356 form a 
src-homology-2 domain (SH2) that recruit signal-relay molecules that activates 
several pathways including the growth factor receptor-bound protein (GRB2) – 
RAS, PI3K – AKT, SRC and RAC1 pathway (Comoglio et al., 2008)(Organ & 
Tsao, 2011). Another protein that cooperates with c-MET is the hyaluronan recep-
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tor CD44 that serve as a linker between the intracellular actin cytoskeleton and the 
extracellular matrix (Trusolino et al., 2010). HGF and c-MET is especially active 
during embryonic development, but is also highly active during wound healing 
and following organ damage for reconstruction of injured tissue (Comoglio et al., 
2008). Overexpression of c-MET has been found in several human primary tumors 
including primary brain tumors (Moriyama et al., 1998). Overexpression of the 
protein has been reported as a result of heritable activating mutations, but in the 
majority of humans with increased expression of c-MET, the effect is due to tran-
scriptional up-regulation. HGF that is expressed throughout the body is also able 
to activate the transcription of c-MET, and support the spread of cancer cells 
through paracrine positive feedback (Comoglio et al., 2008). In GBM, HGF acting 
in an autocrine fashion has been shown to activate c-MET transcription (Koochek-
pour et al., 1997). c-MET’s involvement in several pathways and downstream 
mediators involved in DNA repair and tumor development, makes it a perfect tar-
get for cancer therapies.  
 
HGF and c-MET inhibition. Several strategies have been proposed for c-MET 
inhibition including HGF antagonist and HGF or c-MET neutralizing antibodies. 
Normally, when the ligand attaches to the c-MET receptor a dimerization causes 
phosphorylation in catalytic tyrosine residues. This can be prevented by small 
molecule inhibitors blocking ATP from binding to the kinase active site and pre-
vent phosphorylation and downstream effects (Comoglio et al., 2008). An other 
inhibitor is a soluble recombinant variant of the extracellular MET domain (decoy 
MET) that interacts with both c-MET dimerization and HGF interaction with c-
MET (Michieli et al., 2004).  
 
Immunotherapy targeting c-MET. Antibodies directed against HGF and c-MET 
can prevent the binding of ligand to receptor and also induce down regulation of 
MET. One human monoclonal IgG2 antibody (AMG102) has entered clinical trials 
phase II against advanced glioblastoma (Buchanan et al., 2011). The results 
from these trials suggest that AMG102 has a limited effect when used as mono-
therapy, and later phase trials were not performed. AMG102 will however still be 
studied in combination trials in human cancers. (Martens et al., 2006) 
One problem using antibodies, is their intrinsic agonistic effect and that this can 
cause activation instead of inhibition of targeted receptor (Martens et al., 2006). 
Another problem is that resistance can be reached and the tumor become even 
more persistent (Liu et al., 2010).      
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2.6 New findings in canine gliomas 
Current GWAS, using over 170,000 SNPs, in canine glioma have reported three 
new genes that are strongly associated with development of glioma. The study was 
carried out looking at several different breeds. The fact that glioma is overrepre-
sented in certain brachycephalic (short-nosed) dog breeds compared with other 
breeds, is a strong indication that glioma development is partly caused by genetic 
factors increased in frequency in the high-risk breeds. This provides an excellent 
opportunity to identify the genetic risk factors for glioma development by employ-
ing GWAS approaches. Two strongly associated SNPs were found in introns of 
two genes that biologically can be associated with cancer. Gene mapping of canine 
chromosome 1 (CFA1) and canine chromosome 26 (CFA26), where the two SNPs 
were found, proposes that one SNP was associated with brachycephaly and the 
other one with glioma. Across-breed GWAS of the CFA26 locus associated with 
glioma identified mutations in genes already associated with human cancer (Truvé, 
2012). 
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3 Discussion and future prospects 
Dogs and humans diagnosed with malignant glioma have a very low survival rate 
after five years. Today’s treatments using surgery in combination with radiation 
and chemotherapy is not sufficient and the search for new treatments and classifi-
cation systems for early diagnosis are highly desired. GWAS and NGS have pro-
vided us with important information by identifying genetic risk factors underlying 
the development of glioma, which opens new possibilities to develop detection 
and individualized treatment methods at an early stage of tumor development. 
Several different therapies have been suggested for tumor suppression, and new 
computational models have been made for prediction of diagnosis, glioma devel-
opment and prognosis. Gene therapies against glioma constitutes a very exiting 
prospect, by the delivery of genes into the tumor using viral vectors that will en-
hance tumor cell death or enhance cytokines such as interferons or tumor necrosis 
factors that will elicit the immune response against the tumor. Still, gene therapies 
are in an early stage of development and trials, despite great efforts of researchers 
all over the world. Gene therapies poses some great challenges; the gene has to be 
delivered to tumor cells exclusively, the therapeutic gene also needs to be activat-
ed in these cells and then avoid getting silenced, the delivery of genes can also 
trigger the immune system causing serious illness, and genes delivered with the 
goal of becoming a part of the targeted cell’s genome can integrate in the wrong 
location and disrupt the function of another important gene. The latter example 
was actually the case in a gene therapy trial of a group of human patients affected 
by an immunodeficiency. In some of the patients receiving the correcting gene 
therapy the integrating lantivirus vector integrated within a gene that caused dis-
ruption of gene function and subsequent development of T cell lymphomas. This 
led to a moratorium of this type of gene therapy. Gene therapy in clinical trials is 
today tested in human patients with already bad survival prognosis, which is a 
limited number of patients. Good model animals are fundamental for the chance of 
progressing into further trials.            
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The domestic dog is an excellent model species for complex human diseases such 
as glioma, due to their similarities in physiology and natural development of dis-
eases in a similar fashion as in humans. Using dogs as a model would accelerate 
the genetic studies and drug development due to reduced genetic variations in 
breeds, shorter lifespan and more offspring’s. As a result; mutations, biomarkers 
and endpoints would be identified more efficiently compared with humans. Using 
dogs as models would also prevent the risk of harming other model animals by 
introducing harmful diseases. However, there are some ethical aspects to take into 
consideration before using dogs as a model, is it morally acceptable to use dogs in 
research in ways that possibly could cause them harm? There are different ways to 
look at this; one way where dogs are moral equals to humans and should be treated 
with the same regulations in research as humans, another way is where there is a 
moral dividing line between humans and dogs and separate regulations should 
exist in therapy research. Genetic research minimally requires a clinical examina-
tion by a veterinary clinician and that a biological sample, usually a blood sample, 
is taken from the individual dog, and consequently implicates less physically con-
tacts with the dog patients compared to clinical trials testing new drugs and treat-
ment options, and is therefor often more accepted. All dogs that participate in such 
studies are privately owned companion dogs and their participation in a genetic 
study is with the consent of the dog owner. All type of research, genetic or clini-
cal, do at some point comprise a physically procedure such as blood sampling, 
clinical examination, some times it involves sampling, usually by biopsies or sur-
gery when needed as a clinical procedure to treat the dog from disease. The latter 
treatment could if problems arise during the surgical procedure, cause the dog 
harm. Obviously, dogs cannot speak for themselves in the matter, and it is crucial 
for us humans to take all aspects into consideration and ask ourselves; is the prob-
lem worth solving and at what price.  
  
c-MET and other growth factors such as EGFR, PDGFR and IGFBP2, have been 
found to be overexpressed in both humans and in dogs with glioma. Gene thera-
pies targeting these genes are proposed as treatment for glioma in humans, but 
have not to my knowledge yet been tested in dogs.  
Immune-therapy via activation of the immune response by delivering agonistic 
CD40 monoclonal antibody (mAb) has been shown to give good response in dogs 
with malignant melanoma. The fact that CD40 is also expressed in the central 
nervous system, suggest that this therapy could be a good combined therapy for 
treatment of glioma.   
Further research and trails in dogs would give a better understanding of the effects 
of gene therapies and prediction of outcomes in humans. Here I propose dogs with 
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malignant glioma as an excellent model for gene therapies such as growth factor 
inhibition and Immune stimulated therapies using agonistic CD40 mAb.    
 
To fully use the dog as a model for glioma in humans, cooperation between sever-
al experts in both human and veterinary medicine including geneticists, bioinfor-
maticians, pharmacologists, biologists, statisticians etc. is necessary. Because can-
cer is a complex disease with multiple genome alterations, new high-level analysis 
methods to find sets of genes that complement each other could speed up the re-
search with the goal of development of improved therapies, better diagnosis and 
treatments, and ultimately better outcomes for glioma patients, in both humans and 
in dogs.  
19 
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